MOLECULAR ONCOLOGY GROUP

CORE TECHNOLOGIES
Molecular Oncology Group

PAOLO G. NUCIFORO
Principal Investigator
Biosketch

The mission of VHIO’s Molecular Oncology Group is to apply state-of-the-art tissue-based technologies to basic, translational, and clinical research with a clear focus on developing and validating novel tumor biomarkers for precision medicine in oncology.

Together with VHIO’s Cancer Genomics Group (PI Ana Vivancos), and Oncology Data Science – ODysSey Group (PI Rodrigo Dienstmann), along with Susana Aguilar and Jenifer Gonzalez, our group participates in VHIO’s Molecular Prescreening Program. We molecularly profile over 1100 patients per year as candidates for enrolment in early phase clinical trials at our Research Unit for Molecular Therapy of Cancer (UITM) – ”la Caixa” Foundation). We also serve as one of VHIO’s Core Technology Platforms and our laboratory is therefore key to our translational research lines and programs.

We actively participate in all projects involving the use of human tissue collected from patients, including biomarker analyses for patient stratification and inclusion in clinical trials, digital pathology, tissue banking and the development of primary patient-derived xenograft (PDX) models. Our contribution is reflected by several high-impact factor collaborative papers published throughout 2019.

Our group also continues to work both independently as well as in partnership to establish the impact of microbiome in colorectal cancer development and progression. In particular, we are developing a Fusobacterium nucleatum diagnostic assay that permits the simultaneous visualization and quantification of bacteria within tumors.

As a Core Facility we have provided support for approximately 280 clinical studies conducted at Vall d’Hebron, representing around 70% of all currently open trials at our institution. Our involvement in clinical trials ranges from the coordination of sample collection, storage and shipment, developing and running multiple assays for real-time patient inclusion, as well as pharmacodynamic monitoring and dose finding.

In 2019 we performed more than 4000 molecular determinations on samples for patient inclusion in clinical trials, and over 23,000 tests to support basic and translation research. We have also served as the central laboratory of choice for 10 international studies, and successfully maintained the prestigious ISO15189 accreditation that endorses quality and competence.

STRATEGIC GOALS

  • Discovery and validation of novel biomarkers using tissue-based technologies.
  • Serve as a core facility for VHIO research programs.
  • Act as a central and local laboratory in clinical trials.
  • Apply molecular pathology strategies to support early clinical drug development programs.
  • Define molecular targets epidemiology to improve personalized treatment strategies.

 


HIGHLIGHTS

  • Application of targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer (Scientific Reports 2019).
  • Work-package leader and central laboratory for the Horizon 2020-supported COLOSSUS – Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions.

 


TEAM

  • Principal Investigator
    • Paolo G. Nuciforo
  • Attending Physicians
    • Roberta Fasani
    • Sara Siomenetti
  • Laboratory Supervisor
    • Jose Antonio Jiménez
  • Laboratory Assistant
    • Mª Ángeles Díaz
  • Post-Doctoral Fellow
    • Francisca Gallego
  • PhD Student
    • Garazi Serna
  •  Technicians
    • Lidia Alonso
    • Clara Castán
    • Eloy Garcia
    • Xavier Guardia
    • Paola Martínez
    • Stefania Napoli
    • Gertrudis Sánchez
    • Lidia Sánchez Flores
    • César Javier Sevillano
  • Students
    • Audrey Detolle
    • Esther Farell
    • Kristiana Plamenova

Most relevant scientific publications

  • Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2019 Sep;20(9):1226-1238. doi: 10.1016/S1470-2045(19)30334-1.
  • Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho JL, Gil Gil M, Bermejo B, Patt DA, Ciruelos E, de la Peña L, Xu N, Wongchenko M, Shi Z, Singel SM, Isakoff SJ. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019 Aug 1;30(8):1289-1297.
  • Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E. A predictive model of pathologic response based on tumor cellularity and tumor-infiltratinglymphocytes (CelTIL) in HER2- positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol. 2018 Jan 1;29(1):170-177.
  • Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, Chipashvili O, Hagan T, Walker M, Ramachandran A, Diosdado B, Serna G, Mulet N, Landolfi S, Ramon Y Cajal S, Fasani R, Aguirre AJ, Ng K, Élez E, Ogino S, Tabernero J, Fuchs CS, Hahn WC, Nuciforo P, Meyerson M. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 2017 Dec 15;358(6369):1443-1448. doi: 10.1126/science.aal5240. Epub 2017 Nov 23.
  • Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E. A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol. 2017 Oct 12. doi: 10.1093/annonc/mdx647. [Epub ahead of print].
  • Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, Unda M, Torrano V, Cabrera D, van Liempd SM, Cendon Y, Castro E, Murray S, Revandkar A, Alimonti A, Zhang Y, Barnett A, Lein G, Pirman D, Cortazar A, Arreal L, Prudkin L, Astobiza I, Valcarcel-Jimenez L, Zuñiga-García P, Fernandez-Dominguez I, Piva M, Caro-Maldonado A, Sánchez-Mosquera P, Castillo-Martín M, Serra V, Beraza N, Gentilella A, Thomas G, Azkargorta M, Elortza F, Farràs R, Olmos D, Efeyan A, Anguita J, Muñoz J, Falcón-Pérez JM, Barrio R, Macarulla T, Mato JM, Martinez-Chantar ML, Cordon-Cardo C, Aransay AM, Marks K, Baselga J, Tabernero J, Nuciforo P, Manning BD, Marjon K, Carracedo A. MTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature. 2017 Jul 6;547(7661):109-113.
  • Llombart-Cussac A, Cortes J, Paré L, Galvan P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017 Apr;18(4):545-554. doi: 10.1016/S1470-2045(17)30021-9. Epub 2017 Feb 24.
  • Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, Jimenez J, Vicario R, Cecchi F, Hoos W, Burrows J, Hembrough T, Ferreres JC, Perez-Garcia J, Arribas J, Cortes J, Scaltriti M. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Mol Oncol. 2016;10(1):138-147.
  • Prat A, Galván P, Jiménez B, Buckingham W, Jeiranian HA, Schaper C, Vidal M, Alvarez M, Díaz S, Ellis C, Nuciforo P, Ferree S, Ribelles N, Adamo B, Ramón y Cajal S, Peg V, Alba E. Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.Clin. Cancer Res. 2016 Feb; 22(3): 560-6
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodón J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Pálmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin. Cancer Res. 2016 Feb; 22(3): 644-56
  • Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart M, Baselga J. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin. Cancer Res. 2015 Feb; 21(3): 569-76
  • Prudkin L, Nuciforo P. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic. Cell Oncol (Dordr) 2015 Feb; 38(1): 39-48
  • García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodriguez O, Grueso J, Anton P, Guzman M, Aura C, Nuciforo P, Jessen K, Argiles G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Pálmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin. Cancer Res. 2015 Dec; 21(24): 5499-510
  • Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, Martínez-Barriocanal Á, Navarro Jiménez A, Aura C, Burgues O, Lluch A, Cortes J, Nuciforo P, Rubio IT, Marangoni E, Deeds J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J. Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS ONE 2015; 10(6): e0129876
  • Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Nucifero P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol 2015 Jul; 1(4): 448-54
  • Herrero A, Pinto A, Colón-Bolea P, Casar B, Jones M, Agudo-Ibáñez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizán EM, Horváth Z, Orfi L, Pineda-Lucena A, Bony E, Keri G, Rivas G, Pazos A, Gozalbes R, Pálmer HG, Hurlstone A, Crespo P. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell 2015 Aug; 28(2): 170-82
  • Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Quantification of HER family receptors in breast cancer. Breast Cancer Res. 2015; 17: 53Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, Jimenez J, Vicario R, Cecchi F, Hoos W, Burrows J, Hembrough T, Ferreres JC, Perez-Garcia J, Arribas J, Cortes J, Scaltriti M. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Mol Oncol. 2016;10(1):138-147. Epub 2015 Sep 15.
  • Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol. 2015;1(4):448-454. Erratum in: JAMA Oncol. 2015;1(8):1172.
  • Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Quantification of HER family receptors in breast cancer. Breast Cancer Res. 2015;17:53.
  • Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Peña L, Ellis C, Eidtmann H, Piccart-Gebhart MJ, Scaltriti M, Baselga J. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Ann Oncol. 2015;26(7):1494-1500.

All publications

  •  Nuciforo, Paolo Giovanni; Pascual, T; Cortes Castan, Javier; Llombart-Cussac, A; Fasani, Roberta; Paré, L; Antunes de Melo E Oliveira, Mafalda; Galvan Jurado, Patricia; Martínez, N; Bermejo, B; Vidal Losada, Mª Jesús; Pernas, S; López, R; Muñoz, M; Garau, I; Manso, L; Alarcón, J; Martínez, E; Rodrik-Outmezguine, V; Brase, J C; Villagrasa, P; Prat, A; Holgado, E. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol. 2018 Jan 01. Doi: 10.1093/annonc/mdx647.
  • De Mattos Arruda, Leticia; Ng, Charlotte K Y; Piscuoglio, Salvatore; Gonzalez-Cao, Maria; Lim, Raymond S; De Filippo, Maria R; Fusco, Nicola; Schultheis, Anne M; Ortiz, Carolina; Viteri, Santiago; Arias Piñeiro, Alexandra; Macedo, Gabriel S; Antunes de Melo E Oliveira, Mafalda; Gomez Pardo, Patricia; Teixidó, Cristina; Nuciforo, Paolo Giovanni; Peg, Vicente; Saura Manich, Cristina; Ramon Y Cajal, Santiago; Casas, Francesc Tresserra; Weigelt, Britta; Cortes Castan, Javier; Seoane Suarez, Joan; Reis-Filho, Jorge S. Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget. 2018 Apr 17. Doi: 10.18632/oncotarget.25041.
  • Cruz Zambrano, Cristina; Castroviejo Bermejo, Cristina; Gutierrez Enriquez, Sara Iliana; Llop Guevara, Alba; Ibrahim, Y H; Gris Oliver, Albert; Bonache Real, Sandra; Morancho Armisen, Beatriz; Bruna, A; Rueda, O M; Lai, Z; Polanska, U M; Jones, G N; Kristel, P; de Bustos, L; Guzman, Marta; Rodriguez Ferreiro, Olga; Grueso Gracera, Judit; Montalban Canudas, Gemma; Caratu, Ginevra; Mancuso, Francesco Mattia; Fasani, Roberta; Jimenez, Jose; Howat, W J; Dougherty, B; Vivancos Prellezo, Ana; Nuciforo, Paolo Giovanni; Serres-Créixams, X; Rubio, I T; Oaknin Benzaquen, Ana; Cadogan, E;. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018 May 18. Doi: 10.1093/annonc/mdy099.
  • Capdevila Castillon, Jaume ; Mayor Ferreras, Regina; Mancuso, Francesco Mattia; Iglesias, C; Caratu, Ginevra; Matos Garcia, Ignacio; Zafón, C; Hernando Cubero, Jorge; Petit, A; Nuciforo, Paolo Giovanni; Cameselle-Teijeiro, J M; Álvarez, C; Recio, J A; Tabernero Caturla, Josep; Matias-Guiu, X; Vivancos Prellezo, Ana; Seoane Suarez, Joa. Early evolutionary divergence between papillary and anaplastic thyroid cancers. Ann Oncol. 2018 June 1. Doi: 10.1093/annonc/mdy123.
  • Allen, W L; Dunne, P D; McDade, S; Scanlon, E; Loughrey, M; Coleman, H; McCann, C; McLaughlin, K; Nemeth, Z; Syed, N; Jithesh, P; Arthur, K; Wilson, R; Coyle, V; McArt, D; Murray, G I; Samuel, L; Nuciforo, Paolo Giovanni; Jimenez Jose; Argiles Martinez, Guillermo; Diesntmann, Rodrigo; Tabernero Caturla, Josep; Messerini, L; Nobili, S; Mini, E; Sheahan, K; Ryan, E; Johnston, P G; Van Schaeybroeck, S; Lawler, M; Longley, D B. Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy. JCO Precis Oncol. 2018 June 13. Doi: 10.1200/PO.17.0024.1
  • Saei, Azad; Palafox Sanchez, Marta; Benoukraf, Touati; Kumari, Nishi; Jaynes, Patrick William; Iyengar, Prasanna Vasudevan; Muñoz Couselo, Eva; Nuciforo, Paolo Giovanni; Cortes Castan, Javier; Nötzel, Christopher; Kumarakulasinghe, Nesaretnam Barr; Richard, John Lalith Charles; Bin Adam Isa, Zul Fazreen; Pang, Brendan; Guzman, Marta; Siqin, Zhou; Yang, Henry; Tam, Wai Leong; Serra Elizalde, Violeta; Eichhorn, Pieter Johan Adam. Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. J Exp Med. 2018 Jul 2 Doi: 10.1084/jem.20171960.
  • Cedres Perez, Susana; Felip Font, Enriqueta; Cruz Zambrano, Cristina; Martinez De Castro, Ana Maria; Pardo Aranda, Nuria; Navarro Mendivil, Alejandro; Martinez Marti, Alexandre; Remon Masip, Jordi; Zeron Medina, Jorge; Balmaña Gelpi, Judith; Llop Guevara, Alba; Miquel Aymar, Josep Maria; Sansano, Irene; Nuciforo, Paolo Giovanni; Mancuso, Francesco Mattia; Serra Elizalde, Violeta; Vivancos Prellezo, Ana. Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. J Natl Cancer Inst. 2018 August 1. Doi: 10.1093/jnci/djy012.
  • Puig Borreil, Isabel; Tenbaum, Stephan Paul; Chicote Ramos, Irene; Arques Casamitjana, Oriol; Martinez-Quintanilla Martinez, Jordi; Cuesta Borras, Estefania; Ramírez, Lorena; Gonzalo, Pilar; Soto, Atenea; Aguilar, Susana; Eguizabal, Cristina; Caratu, Ginevra; Prat Aparicio, Aleix; Argiles Martinez, Guillermo; Landolfi, Stefania; Casanovas, Oriol; Serra Elizalde, Violeta; Villanueva, Alberto; Arroyo, Alicia G; Terracciano, Luigi; Nuciforo, Paolo Giovanni; Seoane Suarez, Joan; Recio, Juan A; Vivancos Prellezo, Ana; Dienstmann, Rodrigo; Tabernero Caturla, Josep; Garcia Palmer, Hector. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. J Natl Cancer Inst. 2018 August 31. Doi: 10.1172/JCI96393.
  • Rius Ruiz, Irene; Vicario, Rocio; Morancho Armisen, Beatriz; Bernado Morales, Cristina; Arenas, Enrique J; Herter, Sylvia; Freimoser-Grundschober, Anne; Somandin, Jitka; Sam, Johannes; Ast, Oliver; Barriocanal, Águeda Martinez; Luque Garcia, Antonio Miguel; Escorihuela Baez, Marta; Varela Tang, Ismael; Cuartas Maza, Mª Isabel; Nuciforo, Paolo Giovanni; Fasani, Roberta; Peg, Vicente; Rubio, Isabel; Cortes Castan, Javier; Serra Elizalde, Violeta; Escriva De Romani Muñoz, Santiago; Sperinde, Jeff; Chenna, Ahmed; Huang, Weidong; Winslow, John; Albanell, Joan; Seoane Suarez, Joan; Scaltriti, Maurizio; Baselga Torres, Josep; Tabernero Caturla, Josep; Umana, Pablo; Bacac, Marina; Saura Manich, Cristina; Klein, Christian; Arribas Lopez, Joaquin Vicente. p95HER2-T cell bispecific antibody for breast cancer treatment. Sci Transl Med. 2018 Oct. 3. Doi: 10.1126/scitranslmed.aat1445.
  • De Mattos Arruda, Leticia; Weigelt, B; Cortes Castan, Javier; Won, H H; Ng, C K Y; Nuciforo, Paolo Giovanni; Bidard, F-C; Aura, C; Saura Manich, Cristina; Peg, V; Piscuoglio, S; Antunes De Melo E Oliveira, Mafalda; Smolders, Y; Patel, P; Norton, L; Tabernero Caturla, Josep; Berger, M F; Seoane Suarez, Joan; Reis-Filho, J S. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol. 2018 Nov 01. Doi: 10.1093/annonc/mdx804.
  • Powles, Ryan L; Redmond, David; Sotiriou, Christos; Loi, Sherene; Fumagalli, Debora; Nuciforo, Paolo Giovanni; Harbeck, Nadia; De Azambuja, Evandro; Sarp, Severine; Di Cosimo, Serena; Huober, Jens; Baselga Torres, Josep; Piccart-Gebhart, Martine; Elemento, Olivier; Pusztai, Lajos; Hatzis, Christos. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol. 2018 Nov 01. Doi: 10.1001/jamaoncol.2018.1564.
  • Castroviejo-Bermejo, Marta; Cruz, Cristina; Llop Guevara, Alba; Gutierrez Enriquez, Sara Iliana; Ducy, Mandy; Ibrahim, Yasir Hussein; Gris Oliver, Albert; Pellegrino, Benedetta; Bruna, Alejandra; Guzman, Marta; Rodriguez Ferreiro, Olga; Grueso Gragera, Judit; Bonache, Sandra; Moles-Fernández, Alejandro; Villacampa, Guillermo; Viaplana, Cristina; Gomez Pardo, Patricia; Vidal, Marc; Peg, Vicente; Serres-Créixams, Xavier; Dellaire, Graham; Simard, Jacques; Nuciforo, Paolo Giovanni; Rubio, Isabel T; Dientsmann, Rodrigo; Barrett, J Carl; Caldas, Carlos; Baselga, José; Saura Manich, Cristina; Cortés, Javier; Déas, Olivier; Jonkers, Jos; Masson, Jean-Yves; Cairo, Stefano; Judde, Jean-Gabriel; O’connor, Mark J; Diez Gibert, Orland; Balmaña, Judith; Serra Elizalde, Violeta. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med. 2018 Dec.01 Doi: 10.15252/emmm.201809172.
  • Nuciforo P. The search for simplicity: is this compatible with precision medicine? Ann Oncol 2016. First published online: October 25, 2016 doi: 10.1093/annonc/mdw566.
  • Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017 Apr;18(4):545-554. doi: 10.1016/S1470-2045(17)30021-9. Epub 2017 Feb 24.
  • Cejalvo JM, Martínez de Dueñas E, Galván P, García-Recio S, Burgués Gasión O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, Guerrero-Zotano Á, Muñoz M, Nucíforo P, Vidal M, Pérez RM, Chacón López-Muniz JI, Caballero R, Peg V, Carrasco E, Rojo F, Perou CM, Cortés J, Adamo V, Albanell J, Gomis RR, Lluch A, Prat A. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. Cancer Res. 2017 May 1;77(9):2213-2221. doi: 10.1158/0008-5472.CAN-16-2717. Epub 2017 Mar 1.
  • Grasselli J, Elez E, Caratù G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Viéitez JM, Paéz D, Falcó E, Lopez Lopez C, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2017 Jun 1;28(6):1294-1301. doi: 10.1093/annonc/mdx112.
  • Prat A, Navarro A, Paré L, Reguart N, Galvan P, Pascual T, Martínez A, Nuciforo P, Comerma L, Alos L, Pardo N, Cedrés S, Fan C, Parker JS, Gaba L, Victoria I, Viñolas N, Vivancos A, Arance A, Felip E. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma. Cancer Res. 2017 May 9. pii: canres.3556.2017. doi: 10.1158/0008-5472.CAN-16-3556. [Epub ahead of print].
  • Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero JAnalysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights. Mol Oncol. 2017 Sep;11(9):1263-1272. doi: 10.1002/1878-0261.12099. Epub 2017 Jul 20.
  • Rodon J, Postel-Vinay S, Hollebecque A, Nuciforo P, Azaro A, Cattan V, Marfai L, Sudey I, Brendel K, Delmas A, Malasse S, Soria JC. First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. Eur J Cancer. 2017 Aug;81:142-150. doi: 10.1016/j.ejca.2017.05.007.
  • Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, Unda M, Torrano V, Cabrera D, van Liempd SM, Cendon Y, Castro E, Murray S, Revandkar A, Alimonti A, Zhang Y, Barnett A, Lein G, Pirman D, Cortazar AR, Arreal L, Prudkin L, Astobiza I, Valcarcel-Jimenez L, Zuñiga-García P, Fernandez-Dominguez I, Piva M, Caro-Maldonado A, Sánchez-Mosquera P, Castillo-Martín M, Serra V, Beraza N, Gentilella A, Thomas G, Azkargorta M, Elortza F, Farràs R, Olmos D, Efeyan A, Anguita J, Muñoz J, Falcón-Pérez JM, Barrio R, Macarulla T, Mato JM, Martinez-Chantar ML, Cordon-Cardo C, Aransay AM, Marks K, Baselga J, Tabernero J, Nuciforo P, Manning BD, Marjon K, Carracedo A. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature. 2017 Jul 6;547(7661):109-113. doi: 10.1038/nature22964. Epub 2017 Jun 28.
  • Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O’Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162.
  • Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O’Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161.
  • Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2017 Oct 1;28(10):2451-2457. doi: 10.1093/annonc/mdx396.
  • Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E. A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol. 2017 Oct 12. doi: 10.1093/annonc/mdx647. [Epub ahead of print]
  • Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, Chipashvili O, Hagan T, Walker M, Ramachandran A, Diosdado B, Serna G, Mulet N, Landolfi S, Ramon Y Cajal S, Fasani R, Aguirre AJ, Ng K, Élez E, Ogino S, Tabernero J, Fuchs CS, Hahn WC, Nuciforo P, Meyerson M. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017 Dec 15;358(6369):1443-1448. doi: 10.1126/science.aal5240. Epub 2017 Nov 23.
  • Prat A, Galván P, Jiménez B, Buckingham W, Jeiranian HA, Schaper C, Vidal M, Alvarez M, Díaz S, Ellis C, Nuciforo P, Ferree S, Ribelles N, Adamo B, Ramón y Cajal S, Peg V, Alba E. Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.Clin. Cancer Res. 2016 Feb; 22(3): 560-6
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodón J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Pálmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin. Cancer Res. 2016 Feb; 22(3): 644-56
  • Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart M, Baselga J. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin. Cancer Res. 2015 Feb; 21(3): 569-76
  • Prudkin L, Nuciforo P. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic. Cell Oncol (Dordr) 2015 Feb; 38(1): 39-48
  • García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodriguez O, Grueso J, Anton P, Guzman M, Aura C, Nuciforo P, Jessen K, Argiles G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Pálmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin. Cancer Res. 2015 Dec; 21(24): 5499-510
  • Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, Martínez-Barriocanal Á, Navarro Jiménez A, Aura C, Burgues O, Lluch A, Cortes J, Nuciforo P, Rubio IT, Marangoni E, Deeds J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J. Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS ONE 2015; 10(6): e0129876
  • Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Nucifero P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol 2015 Jul; 1(4): 448-54
  • Herrero A, Pinto A, Colón-Bolea P, Casar B, Jones M, Agudo-Ibáñez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizán EM, Horváth Z, Orfi L, Pineda-Lucena A, Bony E, Keri G, Rivas G, Pazos A, Gozalbes R, Pálmer HG, Hurlstone A, Crespo P. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell 2015 Aug; 28(2): 170-82
  • Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Quantification of HER family receptors in breast cancer. Breast Cancer Res. 2015; 17: 53
  • Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortes J. ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep 2015; 5: 8179
  • Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de La Peña L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J. Clin. Oncol. 2015 Apr; 33(12): 1334-9
  • De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF, Seoane J, Reis-Filho JS. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. Mol Oncol 2014 Feb; 8(1): 150-8
  • Dienstmann R, Rodón J, Prat A, Pérez-García J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann. Oncol. 2014 Mar; 25(3): 552-63
  • Parra-Palau JL, Morancho B, Peg V, Escorihuela M, Scaltriti M, Vicario R, Zacarias-Fluck M, Pedersen K, Pandiella A, Nuciforo P, Serra V, Cortes J, Baselga J, Perou CM, Prat A, Rubio IT, Arribas J. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. J. Natl. Cancer Inst. 2014 Nov; 106(11)
  • De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann. Oncol. 2014 Sep; 25(9): 1729-35
  • Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Ramón y Cajal S, del Campo JM, Ramony Cajal S, Felip E, Tabernero J, Cortes J. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep 2013; 3: 3544
  • Belloni B, Lambertini C, Nuciforo P, Phillips J, Bruening E, Wong S, Dummer R. Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system. J. Clin. Pathol. 2013 Feb; 66(2): 124-35
  • Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratù G, Parra JL, De Mattos-Arruda L, Grueso J, Hernandez-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J, Baselga J. Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer Discov 2013 Nov; 3(11): 1238-44
  • Lambertini C, Barzaghi-Rinaudo P, D’Amato L, Schulz S, Nuciforo P, Schmid HA. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies. Regul. Pept. 2013 Nov; 187: 35-41
  • Lucá R, Averna M, Zalfa F, Vecchi M, Bianchi F, La Fata G, Del Nonno F, Nardacci R, Bianchi M, Nuciforo P, Munck S, Parrella P, Moura R, Signori E, Alston R, Kuchnio A, Farace MG, Fazio VM, Piacentini M, De Strooper B, Achsel T, Neri G, Neven P, Evans DG, Carmeliet P, Mazzone M, Bagni C. The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation. EMBO Mol Med 2013 Oct; 5(10): 1523-36
  • Schmid HA, Lambertini C, van Vugt HH, Barzaghi-Rinaudo P, Schäfer J, Hillenbrand R, Sailer AW, Kaufmann M, Nuciforo P. Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors. Neuroendocrinology 2012; 95(3): 232-47
  • Zipser MC, Eichhoff OM, Widmer DS, Schlegel NC, Schoenewolf NL, Stuart D, Liu W, Gardner H, Smith PD, Nuciforo P, Dummer R, Hoek KS. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. Pigment Cell Melanoma Res 2011 Apr; 24(2): 326-33
  • Luise C, Capra M, Donzelli M, Mazzarol G, Jodice MG, Nuciforo P, Viale G, Di Fiore PP, Confalonieri S. An atlas of altered expression of deubiquitinating enzymes in human cancer. PLoS ONE 2011; 6(1): e15891
  • Rustighi A, Tiberi L, Soldano A, Napoli M, Nuciforo P, Rosato A, Kaplan F, Capobianco A, Pece S, Di Fiore PP, Del Sal G. The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer. Nat. Cell Biol. 2009 Feb; 11(2): 133-42
  • Raynaud CM, Jang SJ, Nuciforo P, Lantuejoul S, Brambilla E, Mounier N, Olaussen KA, André F, Morat L, Sabatier L, Soria JC. Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. Ann. Oncol. 2008 Nov; 19(11): 1875-81
  • Colaluca IN, Tosoni D, Nuciforo P, Senic-Matuglia F, Galimberti V, Viale G, Pece S, Di Fiore PP. NUMB controls p53 tumour suppressor activity. Nature 2008 Jan; 451(7174): 76-80
  • Vecchi M, Confalonieri S, Nuciforo P, Viganò MA, Capra M, Bianchi M, Nicosia D, Bianchi F, Galimberti V, Viale G, Palermo G, Riccardi A, Campanini R, Daidone MG, Pierotti MA, Pece S, Di Fiore PP. Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene 2008 Apr; 27(15): 2148-58
  • Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A, Buttitta F, Felicioni L, Nicassio F, Di Fiore PP. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J. Clin. Invest. 2007 Nov; 117(11): 3436-44
  • Vecchi M, Nuciforo P, Romagnoli S, Confalonieri S, Pellegrini C, Serio G, Quarto M, Capra M, Roviaro GC, Contessini Avesani E, Corsi C, Coggi G, Di Fiore PP, Bosari S. Gene expression analysis of early and advanced gastric cancers. Oncogene 2007 Jun; 26(29): 4284-94